Benaroya Research Institute's third annual immunology symposium, "New Horizons in Immunity and Disease," will take place on Tuesday, May 5, 2026. Due to strong interest and enthusiastic support from the immunology community, we’re relocating this year’s event to Bell Harbor International Conference Center in Seattle, a larger venue that will better accommodate our growing audience.
We’re excited to once again bring together leading voices from the local and national immunology research community for a day of collaboration, discovery, discussion and connection. Building on two years of full houses, dynamic presentations, and meaningful dialogue, this year’s symposium is set to continue that momentum.
Mark your calendars and save the date: more details, including program highlights and event speakers, will be shared soon.
Please contact BRI's marketing and communications team via email with any questions.
Keynote Speaker
The 2026 BRI Immunology Symposium welcomes our keynote speaker, Jay Shendure, MD, PhD, Lead Scientific Director, Seattle Hub for Synthetic Biology; Scientific Director, Brotman Baty Institute; Professor, Department of Genome Sciences, University of Washington; Investigator, Howard Hughes Medical Institute.
Past BRI Immunology Symposium Speakers
Check back as we announce the 2026 speakers. Previous speakers at the BRI Immunology Symposium have included:
News
New Genomic Screens Illuminate How Genetic Variants Drive Autoimmune Disease Through T Cells
Read More
New US$3.1 Billion Foundation Takes Big, Long-Term Bets on Bioscience, AI and the Environment
Learn More ➡
New Foundation From Microsoft Cofounder Reveals Inaugural Research Grants, Pledges $500 Million Funding
Learn More ➡
Featured Publications
Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetes
J Clin Invest
T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes
J Immunother Cancer
ATG as disease-modifying therapy for new-onset type 1 diabetes
Lancet
A multi-omics recovery factor predicts long COVID in the IMPACC study
J Clin Invest
Mepolizumab alters gene regulatory networks of nasal airway type-2 and epithelial inflammation in urban children with asthma
Nat Commun
